Skip to content
Review Open access

[Clinical pharmacogenetics and the use of biobanks].

Sep 2026 · Ugeskrift for læger · Vol 188 37, pp. 1-8 · 0 citations
Medicine

TL;DR

The Danish strategy for personalised medicine 2025-2027 includes initiatives for improving the use of pharmacogenetic information to guide drug therapy, and this review emphasises the need for improved infrastructure and data access for physicians.

Abstract

The Danish strategy for personalised medicine 2025-2027 includes initiatives for improving the use of pharmacogenetic (PGx) information to guide drug therapy. While PGx is already in use, its potential to prevent side effects and improve treatment success is not fully realised. 20% of Danish adults are already genotyped, which is a powerful resource, and this review emphasises the need for improved infrastructure and data access for physicians. The experience with return of genetic results is good but must be balanced with considerations on both cost-benefit and clinical effect.

Read PDF

Similar papers

Open access Oct 2026

THE ROLE OF PHARMACOGENETICS IN PREDICTING DRUG RESPONSE AND ADVERSE DRUG REACTIONS

Give the same dose of the same drug to two patients, and one may be cured while the  other is harmed—a problem as old as prescribing itself. Much of that variability is  written in the genome. Pharmacogenetics, the study of how inherited variation modifies  drug response, has matured from a laboratory curiosity into a...

J. Sikarwar, Zunaira Amber, Nada Mohamme et al. · 0 citations
Open access Sep 2026

Targeting Problems and Adhering to Standards: A Pathway to Uniform Clinical Laboratory Processes that Maximize the Benefits of Pharmacogenomics.

Specific laboratory practices that should be discontinued or established and followed as standard practice are proposed and ideal practices that would advance pharmacogenomics in clinical care are proposed.

E. Fieg, Benjamin Kerman, Lucas A. Berenbrok et al. · 0 citations
Open access Sep 2026

Integrating pharmacovigilance, pharmacokinetics and clinical outcomes in clozapine safety science.

Clozapine remains the most effective treatment for treatment-resistant schizophrenia, yet its use is constrained by concerns about safety and preventable adverse outcomes. Evidence on clozapine safety remains fragmented and methodologically heterogeneous, limiting translation into clinical practice. Pharmacovigilance,...

C. de las Cuevas · 0 citations

AFFORDABLE PHARMACOGENOMICS IN

João Fernandes Floriano, Maria Elizabeth Menezes · 0 citations
Review Open access Oct 2026

Historical Perspective and Clinical Implementation of Pharmacogenomics (PGx) Technology with Clinical Decision Support (CDS) in Child and Adolescent Psychiatry

Pharmacogenomics (PGx) uses the variation in a patient’s genetic profile to assist with medication choice, with the goal of shortening the trial-and-error process of prescribing in psychiatry. Over the past few decades, PGx technology has evolved greatly to identify various genetic polymorphisms in drug-metabolizing en...

Rachael Cella, Helen Bian, Alexander Luo et al. · 0 citations
Open access Oct 2026

Advancing Therapeutics for Children with Medical Complexity: The Role of Model-Informed Precision Dosing and Genotype-Stratified Trials.

This work proposes a framework using genotype-stratified trials to characterize pharmacogenetic sources of variability, informing MIDD and MPID models while helping identify additional determinants of therapeutic response in CMC.

R. Gelineau-Morel, J. Leeder, Jonathan B. Wagner · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.